银屑病关节炎患者使用一线或二线IL-17A抑制剂治疗时对依奇珠单抗和司库奇尤单抗的依从性:一项丹麦人群队列研究
该研究基于丹麦风湿病登记库(DANBIO)2014至2021年数据,纳入既往接受过至少一种TNF抑制剂治疗的PsA患者,评估一线或二线IL-17A抑制剂治疗的依从性。共纳入534例一线转换者(司库奇尤单抗510例、依奇珠单抗24例)和102例二线转换者(司库奇尤单抗35例、依奇珠单抗67例)。一线与二线转换者基线特征相似,治疗依从性相似;二线司库奇尤单抗与二线依奇珠单抗转换者依从性也相似。作者认为第一种IL-17A抑制剂治疗失败不应排除第二种IL-17A抑制剂治疗。
要点
- 534例一线转换者中司库奇尤单抗510例、依奇珠单抗24例;102例二线转换者中司库奇尤单抗35例、依奇珠单抗67例。
- 一线与二线转换者的治疗依从性相似。
- 二线司库奇尤单抗与二线依奇珠单抗转换者的治疗依从性相似。
核心结论
- 接受一线或二线IL-17A抑制剂治疗的PsA患者基线特征相似,治疗依从性相似。
- 第一种IL-17A抑制剂治疗失败不应排除第二种IL-17A抑制剂治疗。
研究设计与样本
- 基于丹麦风湿病登记库(DANBIO)2014至2021年数据的人群队列研究。
- 纳入既往接受过一种或多种TNF抑制剂治疗的PsA患者,分为一线IL-17A抑制剂治疗组和二线IL-17A抑制剂治疗组。
- 共纳入534例患者,其中534例一线转换者(司库奇尤单抗510例、依奇珠单抗24例),102例二线转换者(司库奇尤单抗35例、依奇珠单抗67例)。
- 以Kaplan-Meier图报告一线或二线IL-17A抑制剂治疗的依从性。
主要发现
- 基线特征显示一线与二线转换者的HAQ和疼痛视觉模拟评分(VAS)相似。
- VAS全局评分、基于CRP的28关节DAS和既往生物制剂DMARD治疗数量相似,二线转换者数值更高。
- 一线依奇珠单抗治疗患者年龄更小、女性比例更高、病程更短、CRP值更低。
- 一线司库奇尤单抗治疗患者联用MTX的比例更高。
- 一线与二线转换者的治疗依从性相似,二线司库奇尤单抗与二线依奇珠单抗转换者的治疗依从性也相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the effectiveness and tolerability of first- and second-line interleukin (IL)-17A inhibitor treatment in PsA patients from 2014 to 2021 using data from the Danish Rheumatology Registry (DANBIO) by investigating adherence to therapy. METHOD: PsA patients recorded in the DANBIO who received a first- or second-line IL-17A inhibitor treatment were included in this study. All patients included had previously received one or more TNF inhibitor treatment. Baseline characteristics were analysed in subgroups as first-line IL-17A inhibitor treatment and second-line IL-17A inhibitor treatment. Adherence to therapy of first- or second-line IL-17A inhibitor treatments was reported as Kaplan-Meier plots. RESULTS: A total of 534 patients were included in the study, with 534 first-line switchers (secukinumab: 510, ixekizumab: 24) and 102 second-line switchers (secukinumab: 35, ixekizumab: 67). Baseline characteristics showed a similar HAQ and visual analogue scale (VAS) for pain. VAS global, 28-joint DAS with CRP and the previous number of biologic DMARD treatments were similar, with a greater value for second-line switchers. First-line ixekizumab-treated patients present a younger age, greater percentage of females, a lower disease duration and a lower CRP value. Concomitant MTX use was greater for the first-line secukinumab-treated patients. First- and second-line switchers had a similar adherence to therapy. Second-line secukinumab and second-line ixekizumab switchers showed a similar adherence to treatment. CONCLUSION: PsA patients receiving first- or second-line IL-17A inhibitors showed homogeneous baseline characteristics and similar adherence to therapy. Treatment failure of the first IL-17A inhibitor treatment should not preclude a second-line IL-17A inhibitor treatment.
引用
- Hansen RL, Jørgensen TS, Egeberg A, et al. Adherence to therapy of ixekizumab and secukinumab in psoriatic arthritis patients using first- or second-line IL-17A inhibitor treatment: a Danish population-based cohort study. Rheumatology (Oxford). 2024. PMID: 37647648. doi:10.1093/rheumatology/kead434
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。